12th Congress of the European Hematology ... - Haematologica
12th Congress of the European Hematology ... - Haematologica
12th Congress of the European Hematology ... - Haematologica
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
oped mild thrombocytopenia (platelet count between 50.000 and<br />
100.000/µL) without clinical manifestations; <strong>of</strong> <strong>the</strong>se, three cases were<br />
associated with anaemia. In this series <strong>of</strong> AIDS patients we observed 11<br />
cases <strong>of</strong> malignancy (10,2%): 6 Kaposi sarcomas (5 males, 1 female), 3<br />
non-Hodgkin lymphomas (histologically <strong>of</strong> <strong>the</strong> diffuse large cell type),<br />
1 Hodgkin lymphoma and 1 multiple myeloma. They were treated with<br />
chemo<strong>the</strong>rapy according to <strong>the</strong> established protocol and staging. Summary.<br />
In our series <strong>of</strong> AIDS patients <strong>the</strong> most common hematological<br />
complication was anemia (62%), in a few cases associated with neutropenia<br />
or thrombocytopenia. Isolated neutropenia or thrombocytopenia<br />
was uncommon. Kaposi sarcoma was <strong>the</strong> most frequent malignancy<br />
observed (6 cases), followed by non-Hodgkin lymphoma (3 cases).<br />
1314<br />
COMBINATION OF FLUORESCENCE IMMUNOPHENOTYPING AND IN SITU<br />
HYBRIDIZATION TO DETECT CHROMOSOMAL ABERRATIONS IN MULTIPLE MYELOMA<br />
C. Garcia, A. López Martínez, C. Benet Campos, V. Amigo Garcia,<br />
E. Monzó Castellano, J.R. Mayans Ferrer<br />
Hospital Arnau de Vilanova, VALENCIA, Spain<br />
Background. Multiple myeloma (MM) is <strong>the</strong> prototypic monoclonal Bcell<br />
neoplasm that is derived from <strong>the</strong> autonomous proliferation <strong>of</strong> plasma<br />
cells and associated with paraprotein production and osteolytic bone<br />
lesions. Chromosomal abnormalities are among <strong>the</strong> most important prognostic<br />
parameters for patients with MM. However, conventional karyotyping<br />
has been hampered by <strong>the</strong> slow growth <strong>of</strong> MM cells in cell cultures,<br />
and chromosomal abnormalities are <strong>of</strong>ten missed by this technique,<br />
showing normal karyotypes in around 50 to 70% <strong>of</strong> cases. The importance<br />
<strong>of</strong> chromosomal abnormalities in order to determine prognosis and evolution<br />
<strong>of</strong> <strong>the</strong> disease justifies <strong>the</strong> need to detect <strong>the</strong>se abnormalities in all<br />
patients. Rutine FISH (fluorescent in situ hybridization) improves somewhat<br />
this percentage showing aberrations in up to 85% <strong>of</strong> patients. Fluorescence<br />
Immunophenotyping and interphase Cytogenetics as a Tool for<br />
<strong>the</strong> Investigation Of Neoplasms (FICTION) is a new technique that permits<br />
<strong>the</strong> study and counting <strong>of</strong> only plasma cell nuclei, <strong>the</strong>refore improving<br />
<strong>the</strong> sensitivity <strong>of</strong> <strong>the</strong> FISH technique. Aims. The aim <strong>of</strong> this study is <strong>the</strong><br />
comparison <strong>of</strong> standard FISH technique to FICTION technique for <strong>the</strong><br />
detection <strong>of</strong> chromosomal abnormalities in multiple myeloma and monoclonal<br />
gammopathy <strong>of</strong> undetermined significance (MGUS). Methods.<br />
Bone marrow (BM) samples from 6 patients with MM, 3 patients with<br />
MGUS, and one normal bone marrow, used as a control, were obtained.<br />
For <strong>the</strong> detection <strong>of</strong> chromosomal aberrations, FISH on interphase nuclei<br />
with commercially available probes for 13q14, 11q22.3, p53 gene (17p13)<br />
and IgH rearrangements was performed. For all probes applied, 200 nuclei<br />
were counted. Combination <strong>of</strong> fluorescence immunophenotyping, using<br />
an anti-K?L Ig light chain antibody, and in situ hybridization was applied<br />
to all patients, analyzing also 200 nuclei, except for two cases with specially<br />
low percentage <strong>of</strong> plasma cell infiltration, in which, all plasma cells<br />
present in <strong>the</strong> smear were counted.<br />
Table 1.<br />
Results. Median plasma cell infiltration was 25% (1-89%), <strong>of</strong> note, 6<br />
patients presented with less than 25% <strong>of</strong> infiltration. FISH detected 5 chromosomal<br />
aberrations in 4 cases (44%) 2 <strong>of</strong> <strong>the</strong>m with less than 25% <strong>of</strong><br />
infiltration. FICTION was able to detect 12 chromosomal aberrations in<br />
7 patients (77, 7%). In three patients, <strong>the</strong> FICTION revealed a genomic<br />
aberration that hadn´t been detected with FISH (one <strong>of</strong> <strong>the</strong>m with only 4%<br />
<strong>of</strong> infiltration). FISH sensitivity was very low compared to FICTION sensitivity,<br />
being <strong>the</strong> aberration rates 6-22% in FISH and 10-99% in FICTION<br />
analysis. FICTION revealed that only plasma cells presented chromosomal<br />
aberrations. Table 1 shows percentages <strong>of</strong> abnormal cells. Results<br />
higher than 4% have been considered as positives. P:patient, F:FISH,<br />
FC:FICTION. Conclusions. In conclusion, <strong>the</strong> combination <strong>of</strong> immunophe-<br />
12 th <strong>Congress</strong> <strong>of</strong> <strong>the</strong> <strong>European</strong> <strong>Hematology</strong> Association<br />
notyping and FISH on a single cell level demonstrated that only plasma<br />
cells bore chromosomal aberrations and that combined techniques allow<br />
us to increase <strong>the</strong> sensitivity <strong>of</strong> <strong>the</strong> specific genomic aberration.<br />
1315<br />
THE EFFECT OF BLOOD VISCOSITY ON ERYTHROPOIETIN SECRETION<br />
M.L.A. Balea, 1 T. Puscariu, 2 C. Siara, 1 M.I. Balea3 1 Colentina Clonical Hospital, BUCHAREST; 2 Fundeni Institute, BUCHAREST;<br />
3 NIP Pr<strong>of</strong>. Dr. Marius Nasta, BUCHAREST, Romania<br />
Background. Erythropoietin (Epo) is produced primarily in <strong>the</strong> adult<br />
kidney under <strong>the</strong> control <strong>of</strong> an oxygen-sensing mechanism. Besides<br />
hypoxia, <strong>the</strong>re are several factors that modulate Epo production, such as<br />
hypoglycemia, increased intracellular calcium, insulin release, estrogen,<br />
androgenic steroids, and various cytokines. Aims. To demonstrate our<br />
hypo<strong>the</strong>sis that <strong>the</strong> blood viscosity modulate as well Epo production.<br />
Methods. Considering blood viscosity’s importance for kidney function<br />
we have evaluated <strong>the</strong> serum erythropoietin’s level in subjects with<br />
Waldenstrom’s disease and multiple myeloma before starting <strong>the</strong><br />
plasmapheresis program and at 21 days after <strong>the</strong> serum viscosity was<br />
normalized. The analyzed lot had viscosity between 4cp and 12cp and<br />
need plasmapheresis as a regulator <strong>of</strong> <strong>the</strong>ir severe hyper-viscosity syndrome.<br />
The results we obtained denoted constant decrease to <strong>the</strong> low<br />
level <strong>of</strong> normal values and under normal limits <strong>of</strong> serum Epo concentration<br />
for <strong>the</strong> evaluation made before plasmapheresis. We observed a high<br />
correlation between <strong>the</strong> high level serum viscosity and <strong>the</strong> severity <strong>of</strong><br />
Epo’s decrease level. The reevaluation <strong>of</strong> <strong>the</strong> serum erythropoietin concentration<br />
21 days after serum viscosity stabilizing, indicated a constant<br />
increase <strong>of</strong> <strong>the</strong> serum Epo with 68% to 230% (referring to initial values),<br />
<strong>the</strong> average increase being 114%. Our conclusions <strong>of</strong> this stage are: <strong>the</strong><br />
serum viscosity is involved in <strong>the</strong> Epo’s release regulation; <strong>the</strong> hyper-viscosity<br />
represents an inhibitory factor <strong>of</strong> <strong>the</strong> Epo’s release.<br />
1316<br />
THE RELATION BETWEEN CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA<br />
AND THYROID AUTOANTIBODIES<br />
A. Altintas, 1 S. Pasa, 1 E. Parmaksiz2 1 Dicle University Medical Faculty, DIYARBAKIR; 2 Dicle University, Medical<br />
Faculty, DIYARBAKIR, Turkey<br />
Background and Aim. The association between thrombocytopenia and<br />
hyperthyroidism or thyroid autoimmune diseases (TAD) has been<br />
reported but its mechanism is unclear. Thrombocytopenia may be<br />
observed in patients with TAD, especially those with hyperthyroidism.<br />
We designed a prospective study to investigate <strong>the</strong> prevalence <strong>of</strong> antithyroid<br />
and antigliadin autoantibodies in patients with idiopathic thrombocytopenic<br />
purpura (ITP), and to determine <strong>the</strong> frequency <strong>of</strong> overlapping<br />
autoimmune disorders. Patients and Methods. Patients admitted with<br />
chronic ITP to <strong>the</strong> Dicle University <strong>Hematology</strong> policlinic between June<br />
2003 and December 2006 were tested at study entry and followed for<br />
<strong>the</strong> presence <strong>of</strong> antithyroid antibodies, antiendomisium and antigliadin<br />
antibodies. Thyroid, endomisium and gliadin autoantibodies performed<br />
in 68 patient with chronic ITP compared with 92 healthy individuals that<br />
have a normal platelet counts. Results. Thyroid antithyroid autoantibody<br />
(TATA) positivity detected in 26 (38.2%) out <strong>of</strong> 68 patients with chronic<br />
ITP, and 3 out <strong>of</strong> 92 (3.2%) healthy controls. Thyroid antimicrosomal<br />
autoantibody (TAMA) positivity found in 14 out <strong>of</strong> 68 (20.58%) patients<br />
with chronic ITP, and 2 out <strong>of</strong> 92 (2.1%) healthy controls. Both antithyroid<br />
autoantibodies are significantly different from control subjects<br />
(p